235 related articles for article (PubMed ID: 23932486)
1. Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice.
Yamaguchi N; Vanderlaan PA; Folch E; Boucher DH; Canepa HM; Kent MS; Gangadharan SP; Majid A; Kocher ON; Goldstein MA; Huberman MS; Costa DB
Lung Cancer; 2013 Oct; 82(1):31-7. PubMed ID: 23932486
[TBL] [Abstract][Full Text] [Related]
2. Molecular alterations in non-small cell lung carcinomas of the young.
VandenBussche CJ; Illei PB; Lin MT; Ettinger DS; Maleki Z
Hum Pathol; 2014 Dec; 45(12):2379-87. PubMed ID: 25288236
[TBL] [Abstract][Full Text] [Related]
3. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
Kim HR; Shim HS; Chung JH; Lee YJ; Hong YK; Rha SY; Kim SH; Ha SJ; Kim SK; Chung KY; Soo R; Kim JH; Cho BC
Cancer; 2012 Feb; 118(3):729-39. PubMed ID: 21720997
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous diagnostic platform of genotyping EGFR, KRAS, and ALK in 510 Korean patients with non-small-cell lung cancer highlights significantly higher ALK rearrangement rate in advanced stage.
Kim TJ; Park CK; Yeo CD; Park K; Rhee CK; Kim J; Kim SJ; Lee SH; Lee KY; Yoon HK
J Surg Oncol; 2014 Sep; 110(3):245-51. PubMed ID: 24888607
[TBL] [Abstract][Full Text] [Related]
5. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer.
Gainor JF; Varghese AM; Ou SH; Kabraji S; Awad MM; Katayama R; Pawlak A; Mino-Kenudson M; Yeap BY; Riely GJ; Iafrate AJ; Arcila ME; Ladanyi M; Engelman JA; Dias-Santagata D; Shaw AT
Clin Cancer Res; 2013 Aug; 19(15):4273-81. PubMed ID: 23729361
[TBL] [Abstract][Full Text] [Related]
6. Family history of lung cancer in never smokers with non-small-cell lung cancer and its association with tumors harboring EGFR mutations.
Gaughan EM; Cryer SK; Yeap BY; Jackman DM; Costa DB
Lung Cancer; 2013 Mar; 79(3):193-7. PubMed ID: 23273562
[TBL] [Abstract][Full Text] [Related]
7. The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.
Qu Y; Che N; Zhao D; Zhang C; Su D; Zhou L; Zhang L; Wang C; Zhang H; Wei L
Tumour Biol; 2015 Aug; 36(8):6417-24. PubMed ID: 25813151
[TBL] [Abstract][Full Text] [Related]
8. Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas.
Paik PK; Johnson ML; D'Angelo SP; Sima CS; Ang D; Dogan S; Miller VA; Ladanyi M; Kris MG; Riely GJ
Cancer; 2012 Dec; 118(23):5840-7. PubMed ID: 22605530
[TBL] [Abstract][Full Text] [Related]
9. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.
Kim HR; Lim SM; Kim HJ; Hwang SK; Park JK; Shin E; Bae MK; Ou SH; Wang J; Jewell SS; Kang DR; Soo RA; Haack H; Kim JH; Shim HS; Cho BC
Ann Oncol; 2013 Sep; 24(9):2364-70. PubMed ID: 23788756
[TBL] [Abstract][Full Text] [Related]
10. Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium.
Steuer CE; Behera M; Berry L; Kim S; Rossi M; Sica G; Owonikoko TK; Johnson BE; Kris MG; Bunn PA; Khuri FR; Garon EB; Ramalingam SS
Cancer; 2016 Mar; 122(5):766-72. PubMed ID: 26695526
[TBL] [Abstract][Full Text] [Related]
11. Adequacy of lymph node transbronchial needle aspirates using convex probe endobronchial ultrasound for multiple tumor genotyping techniques in non-small-cell lung cancer.
Folch E; Yamaguchi N; VanderLaan PA; Kocher ON; Boucher DH; Goldstein MA; Huberman MS; Kent MS; Gangadharan SP; Costa DB; Majid A
J Thorac Oncol; 2013 Nov; 8(11):1438-1444. PubMed ID: 24128714
[TBL] [Abstract][Full Text] [Related]
12. Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer.
Vanderlaan PA; Yamaguchi N; Folch E; Boucher DH; Kent MS; Gangadharan SP; Majid A; Goldstein MA; Huberman MS; Kocher ON; Costa DB
Lung Cancer; 2014 Apr; 84(1):39-44. PubMed ID: 24513263
[TBL] [Abstract][Full Text] [Related]
13. Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases.
Mak KS; Gainor JF; Niemierko A; Oh KS; Willers H; Choi NC; Loeffler JS; Sequist LV; Shaw AT; Shih HA
Neuro Oncol; 2015 Feb; 17(2):296-302. PubMed ID: 25053852
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer.
Tsao AS; Tang XM; Sabloff B; Xiao L; Shigematsu H; Roth J; Spitz M; Hong WK; Gazdar A; Wistuba I
J Thorac Oncol; 2006 Mar; 1(3):231-9. PubMed ID: 17409862
[TBL] [Abstract][Full Text] [Related]
15. Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients.
Jiang L; Huang J; Morehouse C; Zhu W; Korolevich S; Sui D; Ge X; Lehmann K; Liu Z; Kiefer C; Czapiga M; Su X; Brohawn P; Gu Y; Higgs BW; Yao Y
Cancer Genet; 2013; 206(9-10):330-9. PubMed ID: 24200637
[TBL] [Abstract][Full Text] [Related]
16. Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans.
Reinersman JM; Johnson ML; Riely GJ; Chitale DA; Nicastri AD; Soff GA; Schwartz AG; Sima CS; Ayalew G; Lau C; Zakowski MF; Rusch VW; Ladanyi M; Kris MG
J Thorac Oncol; 2011 Jan; 6(1):28-31. PubMed ID: 21107288
[TBL] [Abstract][Full Text] [Related]
17. Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts.
Li S; Li L; Zhu Y; Huang C; Qin Y; Liu H; Ren-Heidenreich L; Shi B; Ren H; Chu X; Kang J; Wang W; Xu J; Tang K; Yang H; Zheng Y; He J; Yu G; Liang N
Br J Cancer; 2014 May; 110(11):2812-20. PubMed ID: 24743704
[TBL] [Abstract][Full Text] [Related]
18. Lungs don't forget: Comparison of the KRAS and EGFR mutation profile and survival of collegiate smokers and never smokers with advanced lung cancers.
Varghese AM; Sima CS; Chaft JE; Johnson ML; Riely GJ; Ladanyi M; Kris MG
J Thorac Oncol; 2013 Jan; 8(1):123-5. PubMed ID: 23242442
[TBL] [Abstract][Full Text] [Related]
19. Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma.
Sun JM; Lira M; Pandya K; Choi YL; Ahn JS; Mao M; Han J; Park K; Ahn MJ; Kim J
Lung Cancer; 2014 Feb; 83(2):259-64. PubMed ID: 24300132
[TBL] [Abstract][Full Text] [Related]
20. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E
BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
